Skip to main content

Market Overview

JPMorgan's Take On Big Pharma's New ASCO Abstracts

JPMorgan's Take On Big Pharma's New ASCO Abstracts

Abstracts for the ASCO 2016 meeting were released on Wednesday evening. With the event only a couple of weeks away, JPMorgan analyst Chris Schott took a look at what investors can expect from the ASCO presentations of four big-name pharma companies.

For Eli Lilly and Co (NYSE: LLY), ASCO will be all about single-agent data for Abemaciclib, which Schott sees as “clearly very active in breast cancer.” In addition, Schott is still awaiting combo data from MONARCH-2 and -3.

Related Link: 5 Cognitive Biases That Are Killing Your Investment Returns

For Bristol-Myers Squibb Co (NYSE: BMY), Schott was impressed by the two-year survival data for Opdivo in 2L NSCLC. The updated data in the new abstract shows an overall two-year survival rate of 29 percent in non-sq and 23 percent in sq-NSCLC, higher than the respective 16 and 8 percent Docetaxel survival rates.

When it comes to Pfizer Inc. (NYSE: PFE), the highlight of ASCO will be the confirmatory phase III data for Ibrance. The abstract indicates that Pfizer has repeated the efficacy of its phase II PALOMA-1 study, achieving a mPFS of 24.8m, an ORR of 42.1 percent and CBR of 84.9 percent.

Finally, Merck & Co., Inc. (NYSE: MRK) reported some encouraging early-stage data on a Keytruda+ chemo study. The Keytruda combo study showed an uptick in ORR to 57 percent across a number of chemo regimes versus the 43 percent ORR reported last year.

JPMorgan has an Overweight rating on Bristol-Myers, Pfizer and Merck.

Disclosure: The author holds no position in the stocks mentioned.

Latest Ratings for LLY

Apr 2021Morgan StanleyMaintainsOverweight
Apr 2021MizuhoMaintainsBuy
Apr 2021BarclaysMaintainsOverweight

View More Analyst Ratings for LLY
View the Latest Analyst Ratings


Related Articles (BMY + LLY)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas News Events Analyst Ratings Trading Ideas General Best of Benzinga

Latest Ratings

FIBKStephens & Co.Downgrades
LEAFCanaccord GenuityDowngrades8.5
AGMSidoti & Co.Downgrades115.0
KEXGabelli & Co.Downgrades
OCGNCantor FitzgeraldDowngrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at